Rhett Wilkerson: Biosimilars and Patient Costs for Cancer Care

Video

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses the role biosimilars have to play in reducing patient costs.

Transcript

Yeah, absolutely. And we've already seen that as well. A lot of the insurance companies are starting to dictate which biosimilars we switch to and when. I think it's a great benefit to the patient as well if we can find them something that is going to do the job as well and is appropriate and payable. You know, we're interested in in pursuing that option as well for the patients.

Related Videos
Chelsee Jensen, PharmD, BCPS
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD
Fran Gregory, PharmD, MBA
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Ryan Haumschild, PharmD, MS, MBA
Related Content
© 2023 MJH Life Sciences

All rights reserved.